Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Formerly About Applied Materials -- Ignore unavailable to you. Want to Upgrade?

To: Jacob Snyder who wrote (62474)	3/28/2002 9:38:21 PM
From: StanX Long	Read Replies (1) \| Respond to of 70976

Thanks Jacob for the input WPI. I am heavy in cash now and I'm looking for another sector. As always, I'll do my DD before investing. Thanks Stan

To: Jacob Snyder who wrote (62474)	3/29/2002 11:20:58 AM
From: mitch-c	Respond to of 70976

OT - WPI Looks like they got some bad news Thursday ... (Edit - your initial comments took this into account, when I looked back at them.) news.moneycentral.msn.com "NEW YORK, March 28 (Reuters) - Watson Pharmaceuticals Inc. (WPI) said on Thursday its Oxytrol patch to treat overactive bladder was rejected by U.S. regulators, a setback for the company's plan to shift its focus from generic drugs to its own branded pharmaceuticals. The disappointment forced Watson to lower its revenue forecast for the year, but the company raised 2002 earnings projections slightly because it will not spend money to launch the product. Shares of Watson slumped $3.65, or 11.9 percent, to $27.09 on the New York Stock Exchange. ..."

To: Jacob Snyder who wrote (62474)	3/29/2002 5:49:57 PM
From: Sam Citron	Read Replies (1) \| Respond to of 70976

OT Jacob (WPI), Two nonapprovable letters within two days is quite a blow. You are obviously not shy of blood! I hope it turns out to be an excellent entry opportunity for you. Do you happen to know where I can get statistics on FDA approvables/nonapprovables this year and how this number has been trending over the past several years? Also, do you happen to know how closely it is possible for an investor to time the event risk of an approval/nonapproval, i.e., is it possible to say with any degree of certainty that Company X will get a yea or nay from the FDA next Thursday on Drug z? TIA, Sam